Dr. Nayyar joined Turning Point Therapeutics in June 2018 as Vice President of Regulatory Affairs. Previously, he was Associate Vice President of Regulatory Affairs and Quality Assurance at aTyr Pharma, where he was responsible for the corporate regulatory and quality functions. Prior to aTyr, Dr. Nayyar worked for companies such as Pfizer, Spectrum and Halozyme, where he led and implemented strategic regulatory paths (nonclinical, clinical, and CMC) and obtained worldwide approvals for landmark products such as Herceptin SC, MabThera SC, Rituxan Hycela and HyQvia. He also created development strategies for numerous Phase 1-3 molecules, Phase 4 life-cycle management (namely Fusilev, Zevalin and Hylenex) and companion diagnostics. He has led the approval of several orphan drugs and gained fast-track designations from FDA and EMA. Dr. Nayyar participated in due diligence activities of many high-value partnerships/collaborations at Pfizer and Halozyme. He earned a Ph.D. in Organic Chemistry from the Delhi University (India) and an MBA from University of Phoenix. He also holds a Regulatory Affairs Certification (RAC).